Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia

被引：30

作者：

Marani, Carlo ^{[1
]}

Clavio, Marino ^{[1
]}

Grasso, Raffaella ^{[1
]}

Colombo, Nicoletta ^{[1
]}

Guolo, Fabio ^{[1
]}

Kunkl, Annalisa ^{[2
]}

Ballerini, Filippo ^{[1
]}

Giannoni, Livia ^{[1
]}

Ghiggi, Chiara ^{[1
]}

Fugazza, Giuseppina ^{[1
]}

Ravetti, Jean-Louis ^{[2
]}

Gobbi, Marco ^{[1
]}

Miglino, Maurizio ^{[1
]}

机构：

[1] IRCCS AOU S Martino IST, Dept Hematol & Oncol, Genoa, Italy

[2] IRCCS AOU S Martino IST, Dept Pathol, Genoa, Italy

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷 / 12期

关键词：

Acute myeloid leukemia; Minimal residual disease; Flow-cytometry; Wilms' tumor gene; Prognosis; Early response assessment; PROGNOSTIC-SIGNIFICANCE; RISK STRATIFICATION; GENE-EXPRESSION; RT-PCR; DIAGNOSIS; PREDICTS; SURVIVAL; RELAPSE; TIME; AML;

D O I：

10.1016/j.leukres.2013.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifty uniformly treated adult AML patients were analyzed with respect to pre-treatment and post-induction risk factors. Forty-two patients achieving complete hematological remission were assessed for minimal residual disease (MRD) by WT1 gene expression; 34 by flow-cytometry (flow-MRD). Patients who were flow-MRD negative had a better 3-year disease-free (DFS; 79.5% vs. 27.3%; p =.032) compared with patients who were still positive after induction. Interestingly, DFS of flow-MRD positive patients was not related to the amount of flow-detected clone population (>= or < 1%, p =.41) but to WT1 reduction (Delta WT1, 3-year DFS; 46.2% vs. 0% if Delta WT1 was >= or < of 1.5 log, p =.001). In AML, combining MRD results provided by WT1 quantification and flow-cytometry improves the reliability of MRD-based prognostic stratification. Similar analyses by further larger studies should be advocated. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：1606 / 1611

页数：6

共 50 条

[41] Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia
Buccisano, Francesco
Maurillo, Luca
Spagnoli, Alessandra
Del Principe, Maria Ilaria
Fraboni, Daniela
Panetta, Paola
Ottone, Tiziana
Consalvo, Maria Irno
Lavorgna, Serena
Bulian, Pietro
Ammatuna, Emanuele
Angelini, Daniela F.
Diamantini, Adamo
Campagna, Selenia
Ottaviani, Licia
Sarlo, Chiara
Gattei, Valter
Del Poeta, Giovanni
Arcese, William
Amadori, Sergio
Lo Coco, Francesco
Venditti, Adriano
BLOOD, 2010, 116 (13) : 2295 - 2303
[42] Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
Y Zhou
M Othus
D Araki
B L Wood
J P Radich
A B Halpern
M Mielcarek
E H Estey
F R Appelbaum
R B Walter
Leukemia, 2016, 30 : 1456 - 1464
[43] Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
Zhou, Y.
Othus, M.
Araki, D.
Wood, B. L.
Radich, J. P.
Halpern, A. B.
Mielcarek, M.
Estey, E. H.
Appelbaum, F. R.
Walter, R. B.
LEUKEMIA, 2016, 30 (07) : 1456 - 1464
[44] WT1 mRNA Level in Peripheral Blood Is a Sensitive Biomarker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia
Sakamoto, Yuichi
Mariya, Yasushi
Sasaki, Sumiko
Teshiromori, Ryuichi
Oshikiri, Toshiyuki
Segawa, Megumi
Ogura, Kazuto
Akagi, Tomoaki
Kubo, Koumei
Kaimori, Mitsuomi
Funato, Tadao
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 219 (02): : 169 - 176
[45] Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients
Shah, Mithun Vinod
Saliba, Rima M.
Jorgensen, Jeffrey L.
Wang, Sa A.
Alousi, Amin M.
Andersson, Borje S.
Bashir, Qaiser
Ciurea, Stefan O.
Kebriaei, Partow
Marin, David
Patel, Keyur P.
Popat, Uday R.
Rezvani, Katy
Rondon, Gabriela
Shpall, Elizabeth J.
Champlin, Richard E.
Oran, Betul
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S33 - S34
[46] COULD WT1 GENE EXPRESSION BE USEFUL MARKER FOR MONITORING OF MINIMAL RESIDUAL DISEASE IN PEDIATRIC ACUTE MYELOID LEUKEMIA?
Ksiazek, Teofila
Balwierz, Walentyna
Wator, Gracjan
Szewczyk, Katarzyna
Klekawka, Tomasz
Matysiak, Michal
Sikorska-Fic, Barbara
Adamkiewicz-Drozynska, Elzbieta
Maciejka-Kapuscinska, Lucyna
Kowalczyk, Jerzy
Wojcik, Beata
Mlynarski, Wojciech
Jasinska, Aleksandra
Szczepanski, Tomasz
Tomaszewska, Renata
Wysocki, Mariusz
Koltan, Sylwia
Sobol, Grazyna
Mizia-Malarz, Agnieszka
Urasinski, Tomasz
Kamienska, Elzbieta
Krawczuk-Rybak, Maryna
Muszynska-Roslan, Katarzyna
Wieczorek, Maria
Karpinska-Derda, Irena
Karolczuk, Grazyna
Pohorecka, Joanna
Chybicka, Alicja
Potocka, Kinga
Badowska, Wanda
PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1038 - 1039
[47] PROGNOSTIC IMPACT OF WT1 GENE EXPRESSION QUANTIFICATION DURING MINIMAL RESIDUAL DISEASE MONITORING OF ACUTE PROMYELOCYTIC LEUKEMIA
Mitrovic, M.
Tosic, N.
Suvajdzic, N.
Djunic, I.
Vidovic, A.
Virijevic, M.
Colovic, N.
Glumac, I.
Kostic, T.
Pavlovic, S.
Elezovic, I.
Tomin, D.
HAEMATOLOGICA, 2015, 100 : 377 - 378
[48] ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) - DETECTION OF MINIMAL RESIDUAL DISEASE (MRD) AT FLOW-CYTOMETRY
ORFAO, A
CIUDAD, J
LOPEZBERGES, MC
LOPEZ, A
VIDRIALES, B
CABALLERO, MD
VALVERDE, B
GONZALEZ, M
SANMIGUEL, JF
LEUKEMIA & LYMPHOMA, 1994, 13 : 87 - 90
[49] WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome
Cilloni, D
Saglio, G
ACTA HAEMATOLOGICA, 2004, 112 (1-2) : 79 - 84
[50] Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia
Ahmed, Sonia
Elsherif, Mariam
Yassin, Dina
Elsharkawy, Nahla
Mohamed, Ayman S.
Yasser, Nouran
Elnashar, Amr
Hafez, Hanafy
Kolb, Edward A.
Elhaddad, Alaa
FRONTIERS IN ONCOLOGY, 2024, 14

← 1 2 3 4 5 →